PMID- 37342259
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230701
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Comparing the effectiveness of long-term use of daily and weekly glucagon-like 
      peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver 
      disease and type 2 diabetes mellitus: a network meta-analysis.
PG  - 1170881
LID - 10.3389/fendo.2023.1170881 [doi]
LID - 1170881
AB  - OBJECTIVE: In the present network meta-analysis (NMA), we aimed to compare the 
      effectiveness of daily and weekly treatment with glucagon-like peptide-1 receptor 
      agonists for patients with nonalcoholic fatty liver disease (NAFLD) and type 2 
      diabetes mellitus (T2DM). METHOD: We used Stata 17.0 for the NMA. Eligible 
      Randomized controlled trials (RCTs) were searched in PubMed, Cochrane, and Embase 
      databases until December 2022. Two researchers independently screened the 
      available studies. The Cochrane Risk of Bias tool was used to assess the risk of 
      bias in the included studies. We used GRADEprofiler (version3.6) to analyze the 
      evidence certainty. Primary outcomes such as liver fat content (LFC), aspartate 
      aminotransferase (AST), and alanine aminotransferase (ALT) levels, as well as 
      secondary outcomes such as gamma-glutamyltransferase (gammaGGT) and body weight, were 
      evaluated. Then, each intervention was ranked by the surface under the cumulative 
      ranking curve (SUCRA). As a supplement, we drew forest plots of subgroup using 
      RevMan (version 5.4). RESULTS: Fourteen RCTs involving 1666 participants were 
      included in the present study. The NMA results showed that exenatide (bid) was 
      the best treatment for improving LFC compared with other agents, liraglutide, 
      dulaglutide, semaglutide (qw) and placebo), and the SUCRA values were 66.8%. 
      Among five interventions (except exenatide (bid) and semaglutide (qw)) evaluated 
      for AST outcome, and six interventions (except exenatide (bid)) evaluated for ALT 
      outcome, semaglutide (qd) was the most effective drug (SUCRA (AST) = 100%, SUCRA 
      (ALT) = 95.6%). The result of LFC in daily group was MD = -3.66, 95% CI [-5.56, 
      -1.76] and in weekly GLP-1RAs group, it was MD = -3.51, 95% CI [-4, -3.02]. As to 
      AST and ALT, the results in daily group versus weekly group were AST: MD = -7.45, 
      95% CI [-14.57, -0.32] versus MD= -0.58, 95% CI [-3.18, 2.01] and ALT: MD = 
      -11.12, 95% CI [-24.18, 1.95] versus MD = -5.62, 95% CI [-15.25, 4]. The quality 
      of evidence was assessed as moderate or low. CONCLUSION: The daily GLP-1RAs may 
      be more effective in primary outcomes. And the daily semaglutide may be the most 
      effective treatment for NAFLD and T2DM among the six interventions.
CI  - Copyright (c) 2023 Yuan, Gao, Yang, Duan, Ren and Song.
FAU - Yuan, Xia
AU  - Yuan X
AD  - Department of Internal Medicine, Graduate School of Hebei Medical University, 
      Shijiazhuang, Hebei, China.
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
FAU - Gao, Zhe
AU  - Gao Z
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
FAU - Yang, Caixuan
AU  - Yang C
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
AD  - Department of Internal Medicine, Graduate School of Hebei North University, 
      Zhangjiakou, Hebei, China.
FAU - Duan, Kaixin
AU  - Duan K
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
AD  - Department of Internal Medicine, Graduate School of Hebei North University, 
      Zhangjiakou, Hebei, China.
FAU - Ren, Luping
AU  - Ren L
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
FAU - Song, Guangyao
AU  - Song G
AD  - Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
LA  - eng
PT  - Comparative Study
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230605
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 9P1872D4OL (Exenatide)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/chemically induced
MH  - Exenatide/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Hypoglycemic Agents
MH  - Network Meta-Analysis
MH  - *Non-alcoholic Fatty Liver Disease/drug therapy/chemically induced
PMC - PMC10277636
OTO - NOTNLM
OT  - alanine aminotransferase
OT  - aspartate aminotransferase
OT  - glucagon-like peptide-1 receptor agonists
OT  - liver fat content
OT  - nonalcoholic fatty liver disease
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/21 13:04
MHDA- 2023/06/23 06:42
PMCR- 2023/01/01
CRDT- 2023/06/21 11:57
PHST- 2023/02/21 00:00 [received]
PHST- 2023/05/22 00:00 [accepted]
PHST- 2023/06/23 06:42 [medline]
PHST- 2023/06/21 13:04 [pubmed]
PHST- 2023/06/21 11:57 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1170881 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jun 5;14:1170881. doi: 
      10.3389/fendo.2023.1170881. eCollection 2023.